Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy.

The article discusses research which examined safety of combined therapeutic use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARB) for diabetic nephropathy. It describes necessity of interventions that would reduce risk of progression from diabetic nephropathy to end-stage renal disease. Brief details relating to study design, participants, and administration of treatment are given. The adverse effects recorded following treatment are reported.